A closer look at U.S. drug pricing risks
STOXX 600 up 0.8%
Paris, Milan bourses outperform
Fed rate cut bets support mood
Wall St futures broadly unchanged
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com
A CLOSER LOOK AT U.S. DRUG PRICING RISKS
Investor concerns over U.S. regulation risks in the healthcare sector are likely to come to the fore again, with talks over Medicare pricing due to be announced and presidential elections only four months away.
Berenberg has taken a closer look at potential pricing risks for Big Pharma stemming from tweaks to the complex U.S. drug payment system. In short, even though it sees cuts of up to 30% for certain drugs, the impact on earnings per share (EPS) is not overly worrying.
"Over the coming months, U.S. drug pricing will feature heavily with the publication of 'maximum fair price' for the first list of 10 part D drugs, the US election, part D redesign and the second list of 15 part D drugs for price negotiation," say analysts at the German bank in a note.
"Selected drugs could see price cuts of 15-20%. However, we conclude that most companies will see a negligible impact on group sales and EPS," they add.
In more detail, Berenberg sees the redesign of the Part D prescription drug benefit as most impactful to EPS.
AstraZeneca AZN.L and AbbVie ABBV.N are the most affected via cancer drugs Tagrisso, Calquence, Lynparza, Imbruvica and Venclexta, it said.
Also, it sees average price cuts of 20% for the first 10 drugs in Part D, ranging, for example, from 30% for Amgen’s AMGN.O Enbrel to 10% for Novartis’s NOVN.S Entresto.
However, the imminent expiries of patents means these cuts will be short lived in most cases, Berenberg reckons.
(Danilo Masoni)
*****
EARLIER ON LIVE MARKETS:
THE GRASS IS GREENER TODAY IN EUROPE CLICK HERE
SUNNY START IN EUROPE CLICK HERE
POWELL SPARKS OPTIMISM ON RATE CUTS CLICK HERE
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
